Radnor Capital Management LLC Grows Stake in Henry Schein, Inc. $HSIC

Radnor Capital Management LLC lifted its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1.6% in the second quarter, Holdings Channel reports. The firm owned 11,415 shares of the company’s stock after buying an additional 180 shares during the period. Radnor Capital Management LLC’s holdings in Henry Schein were worth $834,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of HSIC. Burgundy Asset Management Ltd. increased its stake in shares of Henry Schein by 33.9% during the first quarter. Burgundy Asset Management Ltd. now owns 2,235,429 shares of the company’s stock worth $153,105,000 after purchasing an additional 566,530 shares in the last quarter. Jones Financial Companies Lllp grew its stake in Henry Schein by 24,351.3% during the 1st quarter. Jones Financial Companies Lllp now owns 542,330 shares of the company’s stock valued at $37,144,000 after acquiring an additional 540,112 shares in the last quarter. Ananym Capital Management LP purchased a new stake in Henry Schein during the 4th quarter valued at about $32,628,000. JPMorgan Chase & Co. grew its stake in Henry Schein by 6.5% during the 1st quarter. JPMorgan Chase & Co. now owns 6,373,036 shares of the company’s stock valued at $436,489,000 after acquiring an additional 390,399 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Henry Schein during the 1st quarter valued at about $21,551,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on HSIC. Robert W. Baird reaffirmed a “neutral” rating and set a $72.00 price objective (down previously from $82.00) on shares of Henry Schein in a research note on Monday, July 14th. Barrington Research dropped their price objective on shares of Henry Schein from $86.00 to $78.00 and set an “outperform” rating for the company in a research note on Wednesday, August 6th. Leerink Partners set a $75.00 price objective on shares of Henry Schein in a research note on Monday, July 14th. UBS Group dropped their price objective on shares of Henry Schein from $75.00 to $70.00 and set a “neutral” rating for the company in a research note on Wednesday, August 6th. Finally, Evercore ISI raised shares of Henry Schein from an “in-line” rating to an “outperform” rating and set a $83.00 price objective for the company in a research note on Tuesday, August 26th. Five equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $76.67.

Henry Schein Price Performance

Henry Schein stock opened at $68.39 on Wednesday. The firm has a market cap of $8.29 billion, a PE ratio of 22.06, a price-to-earnings-growth ratio of 2.27 and a beta of 0.86. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.49. The company has a quick ratio of 0.78, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. The company’s 50 day moving average is $69.12 and its two-hundred day moving average is $69.41.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.09). The business had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.22 billion. Henry Schein had a return on equity of 14.36% and a net margin of 3.05%.Henry Schein’s quarterly revenue was up 3.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.23 earnings per share. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. On average, research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.